Vanda misses Q4 revenue but raises guidance on Bysantic opportunity
Fanapt sales climb 24% in 2025; key regulatory decision expected February 21
Vanda Pharmaceuticals reported fourth-quarter revenue of $57.2 million, falling short of analyst expectations of $58.7 million, as the biotechnology company navigated a significant non-cash tax charge that masked underlying business momentum. Shares of the Washington, D.C.-based company, which currently trade at $7.43, have experienced volatility amid mixed earnings results and anticipation of a key regulatory decision next year.
The company posted a GAAP net loss of $2.39 per share, dramatically missing the projected loss of 45 cents per share. However, the shortfall was driven entirely by a one-time $113.7 million non-cash tax charge, which overshadowed operational performance in the quarter ended December 31. When excluding the tax item, Vanda's core business showed continued resilience through its flagship schizophrenia treatment Fanapt.
Fanapt generated $117.3 million in sales for the full year 2025, representing a 24% increase from the previous year. The antipsychotic medication, which Vanda acquired in 2019, has become the company's revenue backbone as it executes a strategy focused on central nervous system disorders and sleep medicine. The growth trajectory in Fanapt sales suggests successful execution in a competitive market where many treatments face generic pressure.
Beyond Fanapt's performance, Vanda achieved regulatory progress with NEREUS, securing approval for the treatment. The company also highlighted its upcoming regulatory milestone for Bysanti, which has a Prescription Drug User Fee Act (PDUFA) target date of February 21, 2026. That date will mark a critical inflection point for Vanda as investors evaluate the company's pipeline potential beyond its existing commercial products.
For 2026, Vanda provided guidance of $230 million to $260 million in revenue, suggesting confidence in continued growth despite the quarterly miss. That guidance range represents a substantial increase from the $212 million in trailing twelve-month revenue and reflects anticipated contributions from both existing product growth and potential new product launches.
Analysts maintain an optimistic outlook on the stock, with a consensus target price of $13.62, according to market data. Three analysts rate Vanda as a buy while one recommends hold, indicating broad but not universal conviction in the company's prospects. The current trading level of $7.43 sits below the midpoint of that target range, implying potential upside if the company executes on its guidance.
Vanda's valuation metrics reflect both growth expectations and current profitability challenges. The company trades at a forward price-to-earnings ratio of 103.09, with a negative PEG ratio of -2.42, suggesting investors are pricing in significant future earnings acceleration. With a market capitalization of approximately $447 million, Vanda remains a mid-cap player in the biotechnology sector with heavy institutional ownership at 74.7%.
The company's 52-week trading range of $3.81 to $9.60 underscores the stock's volatility, which is characteristic of development-stage biotechnology companies. That volatility has been particularly pronounced around regulatory decisions and product approvals, making the February 2026 Bysanti PDUFA date a crucial catalyst for shareholders to monitor.
Vanda's focus on central nervous system disorders positions it in a therapeutic area with high unmet medical needs but also significant competitive pressure. The company's strategy of acquiring and expanding commercialized products like Fanapt, combined with developing novel therapies through its pipeline, aims to create a diversified revenue base that can sustain growth beyond individual product cycles.
Investors will be watching several factors in the coming months: the continued adoption rate of Fanapt, commercial execution around NEREUS, and preparation for the potential Bysanti launch. The company's ability to maintain the 24% growth trajectory demonstrated by Fanapt while managing research and development expenses will be critical to achieving the 2026 guidance targets and narrowing the valuation gap to analyst price targets.